Global Diabetic Macular Edema (DME) Market, By Type (Focal Diabetic Macular Edema (DME), Diffuse Diabetic Macular Edema (DME)), Treatment (Laser Therapy, Anti-VEGF Agents, Steroids, Surgical, Others), Route of Administration (Intravitreal Injections, Intravitreal Implants, Others), Diagnosis (Fluorescein Angiography, Fundus Imaging, Optical Coherence Tomography (OCT), Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.
Market Analysis and Size
In recent years, the diabetic macular edema (DME) market is anticipated to grow rapidly during the forecast period. Diabetic macular edema (DME) is characterized by fluid accumulation in the macula, which is the region of the retina important for vision. Edema can result from the leakage of plasma contents into the surrounding area, causing the accumulation. Diabetic macular edema is one of the primary causes of blindness in diabetic patients, affecting around 12% of type 1 diabetes patients and 28% of type 2 diabetic patients in developing nations in 2011. Controlling blood sugar levels, or glycaemia, lipid levels, and renal function is the conventional treatment for diabetic macular edema. The Diabetes Control and Complications Trial (DCCT) found that individuals who received aggressive glycaemic treatment had a 2.3 percent lower risk of DME.
Data Bridge Market Research analyses that the diabetic macular edema (DME) market was valued at USD 3.02 billion in 2021 and is expected to reach USD 3.93 billion by 2029, registering a CAGR of 3.36% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Diabetes macular edema (DME) is one of the most common causes of diabetic visual loss. It's thought to be caused by the retinal vasculature's hyper-permeability. Diabetic retinopathy severity is associated to macular edema. The pathophysiology and molecular processes involved in the development of diabetic macular edema are complex, necessitating a better knowledge of the disease's pathogenesis and molecular pathways. In recent years, pharmaceutical companies have targeted combinations of many medicines to treat DME, aiming to target separate routes or different phases of the same pathway. Medication and laser surgery are two well-established treatments to preserve the patient's vision and decrease future vision loss.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Focal Diabetic Macular Edema (DME), Diffuse Diabetic Macular Edema (DME)), Treatment (Laser Therapy, Anti-VEGF Agents, Steroids, Surgical, Others), Route of Administration (Intravitreal Injections, Intravitreal Implants, Others), Diagnosis (Fluorescein Angiography, Fundus Imaging, Optical Coherence Tomography (OCT), Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
LEO Pharma A/S (Denmark), Amneal Pharmaceuticals LLC. (US), Glenmark Pharmaceuticals Limited (India), Dr. Reddy's Laboratories Ltd. (India), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Bausch Health Companies Inc. (Canada), Eli Lilly and Company (US), AbbVie Inc. (US), Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Allergan (Ireland), Merck & Co., Inc. (US), Pfizer Inc. (US), GlaxoSmithKline plc (UK), IRIDEX Corporation (US)
|
|
Market Opportunities
|
|
Diabetic Macular Edema (DME) Market Dynamics
Drivers
- Increasing prevalence of diabetes
The rising prevalence of diabetes is anticipated to influence the diabetic macular edema (DME) market's growth during the forecast period. The prevalence rate of diabetic macular edema (DME) in type 2 diabetes patients is higher than in type 1 diabetes patients. Along with this, the growing incidences of hyperlipidaemia, fluid retention, hypertension and kidney diseases are the various medical ailments developing the risk of diabetic macular edema (DME).
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of diabetic macular edema (DME) market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the diabetic macular edema (DME) market. Additionally, high disposable income and favorable reimbursement scenario will result in expanding diabetic macular edema (DME) market. Along with this, rising geriatric population and continuously changing lifestyle will enhance the market's growth rate.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for market growth in diabetic macular edema (DME). Along with this, rising approvals and launches of new diabetic macular edema (DME) drugs will further propel the market's growth rate.
Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the diabetic macular edema (DME) market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the treatment of diabetic macular edema (DME) will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the diabetic macular edema (DME) market. Additionally, a decline in clinical visits due to COVID-19 outbreak and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This diabetic macular edema (DME) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the diabetic macular edema (DME) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
As per the World Health Organization (WHO), there are 15 million DME patients, half of whom are misdiagnosed, and 50 percent of the other 8 million do not have access to eye treatment, putting them at risk of vision loss from clinically significant macular edema (CSME). World Health Organization estimates that there are more than 150 million diabetic individuals globally. However, because of the rising prevalence of diabetes in developed countries, the absolute prevalence of diabetic macular edema (DME) may be rising. DME frequency is projected to decline as patients and health care providers increasingly embrace excellent metabolic management as a therapeutic objective.
Diabetic macular edema (DME) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Diabetic Macular Edema (DME) Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of diabetic macular edema (DME) in recent months.
Recent Development
- In March 2022, Novartis had announced the approval of the European Commission (EC) Beovu (brolucizumab) 6 mg. it is used for treating visual impairment which occurs due to diabetic macular edema (DME). Year one data from the Phase III KESTREL and KITE studies, which compared Beovu (brolucizumab) 6 mg to aflibercept 2 mg in DME patients, were used to gain approval. Beovu was non-inferior to aflibercept in terms of change in best-corrected visual acuity (BCVA) from baseline in KESTREL and KITE, and showed promise for fluid resolution in numerically more DME patients than aflibercept.
Global Diabetic Macular Edema (DME) Market Scope
The diabetic macular edema (DME) market is segmented on the basis of type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Focal Diabetic Macular Edema (DME)
- Diffuse Diabetic Macular Edema (DME)
Treatment
- Laser Therapy
- Anti-VEGF Agents
- Steroids
- Surgical
- Others
Route of Administration
- Intravitreal Injections
- Intravitreal Implants
- Others
Diagnosis
- Fluorescein Angiography
- Fundus Imaging
- Optical Coherence Tomography (OCT)
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Diabetic Macular Edema (DME) Market Regional Analysis/Insights
The diabetic macular edema (DME) market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.
The countries covered in the diabetic macular edema (DME) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the diabetic macular edema (DME) market because of the growing prevalence of diabetes and presence of refined healthcare expenditure in this region. Additionally, presence sophisticated photocoagulation laser manufacturers which is projected to propel the market's growth rate in this region.
Europe is expected to grow during the forecast period due to increasing cases of diabetic macular edema (DME) and rising healthcare expenditure in this region. Also, growing focus of major key players on novel technology is estimated to escalate the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Diabetic Macular Edema (DME) Market Share Analysis
The diabetic macular edema (DME) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to diabetic macular edema (DME) market.
Some of the major players operating in the diabetic macular edema (DME) market are:
- LEO Pharma A/S (Denmark)
- Amneal Pharmaceuticals LLC. (US)
- Glenmark Pharmaceuticals Limited (India)
- Dr. Reddy's Laboratories Ltd. (India)
- AstraZeneca (UK)
- Johnson & Johnson Private Limited (US)
- Bausch Health Companies Inc. (Canada)
- Eli Lilly and Company (US)
- AbbVie Inc. (US)
- Abbott (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Novartis AG (Switzerland)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Allergan (Ireland)
- Merck & Co., Inc. (US)
- IRIDEX Corporation (US)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
SKU-